Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Unknown
Primary summary from verified readiness
- Confidence
- 67% · stale
- Computed at
- 2026-08-20T10:51:29.754123+00:00
- Claimed
- 35
- Reported
- 17
- Verified
- 5
- Gap
- +30
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Weak
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Do not rely on; treat as orphaned asset
- Why
- The lead senolytic clinical asset missed its primary endpoint and its sponsor has been formally dissolved (delisted, liquidation approved, certificate of dissolution effective Sept 2025). The mechanism and safety profile remain mechanistically promising, but with no corporate vehicle and no named acquirer/financing, near-term reliance is unwarranted.
- Next
- Monitor for any acquirer that buys UBX1325 out of Unity's dissolution estate and names a financed Phase 3 plan; until then do not treat foselutoclax as a viable independent senolytic asset — the sponsor no longer exists
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 13
- Tier 1
- 7
- Tier 2
- 6
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 10
- Context
- 1
- Latest observed
- 2025-09-19
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-19 Reading moved from unknown to unknown.